The FDA issued a complete response letter for SYD-101, citing insufficient evidence of effectiveness despite achieving ...

Regeneron is planning to re-apply to the FDA with a new pre-filled syringe manufacturing filler in January 2026.

Greenlight Capital funds returned -3.6% in Q3 2025, net of fees and expenses, compared to 8.1% for the S&P 500 index, ...

At an extravagant reception, hotelier Steve Farzam seemed to literally plunge into marriage, appearing to dive from a helicopter in a rainbow parachute onto the grounds of a luxury hotel north of ...

While mRNA-based COVID-19 vaccines are the best known application of the molecule ... "I was shocked to see this, frankly," ...

COVINGTON, Ky. — The Covington Police Department is facing its 14th federal lawsuit since 2021, accusing the city of negligent hiring and failing to properly train and supervise officers. Seven of the ...

Outlook Therapeutics ( ($OTLK) ) just unveiled an announcement. On November 3, 2025, Outlook Therapeutics announced the resubmission of its ...

After reading Louise Plodinec’s letter to the editor on Oct. 10, I feel it necessary to respond to her assertion that “This year… the SRSRA has also opted not to send notification letters to retirees.

In the PIV Notice, WhiteOak alleges that the claims of 19 EXPAREL patents listed in the FDA’s Orange Book (U.S. Patent Nos.11 ...

Police were investigating a deadly crash in Houston’s eastside. (Copyright 2025 by KPRC Click2Houston - All rights reserved.) HOUSTON – Police were investigating ...

Viridian seeks Priority Review for veligrotug, aiming for a potential mid-2026 commercial launch if approved. Global phase 3 ...